BMP and Other Activin Receptors
Activin receptors transduce signals carried by the TGF-β family of ligands. Such ligands include activin and bone morphogenetic proteins (BMPs). Members of this family are involved in a range of processes, including embryogenesis and tissue homeostasis.
Bone morphogenetic proteins (BMPs) are a group of growth factors belonging to the transforming growth factor-β (TGF-β) superfamily (excluding BMP1). Primarily characterized by their effects on bone and cartilage formation, research has further elucidated a role for BMPs in cell growth and development.
There are currently 20 known BMP isoforms, which form dimers in order to bind a tetrameric receptor complex composed of type I and type II BMP receptor subunits. ALK2, ALK3 and ALK6 function as BMP type I receptors, the latter of which are structurally similar. Three BMP type II receptors have also been identified: BMPR2, and type II and IIB activin receptors (ACVR2A and ACVR2B). ALK2, ACVR2A and ACVR2B also function as receptors for activins.
Signal transduction is continued through Smad proteins. Receptor-regulated Smads (R-Smads) are phosphorylated by activation of type I receptors and form heteromeric complexes with Co-Smads. These complexes regulate the transcription of target genes in the nucleus.View all products for BMP and Other Activin Receptors »
|Gene||Species||Gene Symbol||Gene Accession No.||Protein Accession No.|
|View all BMP and Other Activin Receptor Gene Data »|
Literature for BMP and Other Activin Receptors
A collection of over 750 products for cancer research, the guide includes research tools for the study of:
- Cancer Metabolism
- Epigenetics in Cancer
- Receptor Signaling
- Cell Cycle and DNA Damage Repair
- Invasion and Metastasis
A collection of over 400 products for kinase research, the listing includes inhibitors of:
- Receptor Tyrosine Kinases
- Protein Kinases A, C, D and G
- PI-3 Kinase, Akt and mTOR
- MAPK Signaling
- Receptor Serine/Threonine Kinases
Find multiple products by catalog number
October 30 - November 3, 2016
Boston, MA, USA